Protocol for the clinical management of dry mouth;Tratamiento de la boca seca: Puesta al día

Medicina Oral

Volumn 9, Issue 4, 2004, Pages 273-279

  Silvestre Donar, Francisco Javier ^a,b   Miralles Jordá, Lucia ^a   Martínez Mihi, Victoria ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Dry mouth; Treatment; Xerostomia

Indexed keywords

AMINOFOSTINE; ANETHOLE TRITHIONE; BETHANECHOL; CEVIMELINE; CHLORHEXIDINE; HEXETIDINE; KETAZOLAM; MUSCARINIC AGENT; PILOCARPINE; PYRIDOSTIGMINE; TRICLOSAN; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ARTICLE; DIARRHEA; FLUSHING; HEADACHE; HUMAN; HYPERHIDROSIS; HYPOCALCEMIA; HYPOTENSION; LACRIMATION; NAUSEA; POLYURIA; PRACTICE GUIDELINE; SALIVATION; SIDE EFFECT; URINE INCONTINENCE; VOMITING; XEROSTOMIA;

CLINICAL PROTOCOLS; HUMANS; XEROSTOMIA;

EID: 4143109200     PISSN: 11372834     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. López-Jornet P. Alteraciones de las glándulas salivales. Murcia: Universidad de Murcia 2002. p. 17-25.
2. Navazesh M, Christensen C, Brightman V. Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res 1992;71:1363-9.
3. Guggenheimer J, Moore PA. Xerostomia, etiology, recognition and treatment. J Am Dent Assoc 2003;134:61-9.
4. Silvestre-Donat FJ. La xerostomia. Avances en Odontoestomatol 1990;6:405-9.
5. Bates JF, Adams D. The influence of mental states on the flow of saliva. Arch Oral Biol 1968;13:593-6.
6. Moore PA, Guggenheimer J, Etzel KR, Weyant RJ, Orchard T. Type 1 diabetes mellitus, xerostomia and saliva flow rates. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:281-91.
7. Sreebny LM, Valdini A, Yu A. Xerostomia. Part II: Relationship to nonoral symptoms, drugs and diseases. Oral Surg Oral Med Oral Pathol 1989;68:419-27.
8. Pajukoski H, Meurman JH, Halonen P, Sulkava R. Prevalence of subjective dry mouth and burning mouth in hospitalized elderly patients and outpatiens in relation to saliva, medication and systemic diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:641-9.
9. Taylor TD. Clinical maxillofacial prosthetics. Chicago:Quintessence Publishing Co; 2000. p. 37-52.
10. Sivestre-Donat FJ, Serrano-Martinez C. Implicaciones de la saliva en la salud oral. Archivos de Odontoestomatol 1996;12:647-53.
11. Astor FC, Hanft KI, Ciocon JO. Xerostomia: A prevalent condition in the elderly. Ear Nose Throat J 1999;78:476-9.
12. Torres SR, Peixoto CB, Caldas DM, Silva EB, Akiti T, Nucci M, et al. Relationship between salivary flow rates and candida counts in subjects with xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:149-54.
13. Silvestre-Donat FJ. Infecciones de las glándulas salivales. En: Infecciones de cabeza y cuello. Aguirre JM, Martinez-Conde R (eds). Madrid: SmithKline-Beecham s a; 1994. p. 69-80.
14. Castellanos JL. Xerostomia e hiposalivación: Aspectos clínicos. Pract Odontol 1989;10:29-31.
15. Glass BJ, Van Dis ML, Langlais RP, Miles DA. Xerostomia: Diagnosis and treatment planning considerations. Oral Surg 1984;58:248-52.
16. Kaplan G. Gourgerot-Sjögren syndrome. Diagnostic criteria and therapeutic methods. Presse Med 1999;28:1202-8.
17. Jonsson R, Haga HJ, Gordon TP. Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. Scand J Rheumatol 2000;29:341-8.
18. Fox PC. Management of dry mouth. Dent Clin North Am 1997;41:863-75.
19. Brennan MT, Shariff G, Lockhart PB, Fox PC. Treatment of xerostomia: a systematic review of therapeutic trials. Dent Clin North Am 2002;46:847-56.
20. Koukourakis MI. Aminofostine in clinical oncology:current use and future applications. Anticancer Drugs 2002;13:181-209.
21. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth. Gerodontology 1986;5:75-99.
22. Ben-Aryeh H, Miron D, Berdicevsk YI, Szargel R, Gutman D. Xerostomia in the elderly: prevalence, diagnosis, complications and treatment. Gerodontology 1985;4:77-82.
23. Bergdahl M, Bergdahl J. Low unstimulated salivary flow and subjective oral dryness: association with medication, anxiety, depression and stress. J Dent Res 2000;79:1652-8.
24. Fox PC, van der Ven PF, Baum BJ, Mandel ID. Pilocarpina for the treatment of xerostomia associated with salivary glands dysfunction. Oral Surg Oral Med Oral Pathol 1986;61:243-8.
25. Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995;49:143-55.
26. Fox RI, Konttinen Y, Fisher A. Use of muscarinic agonists in the treatment of Sjögren's syndrome. Clin Immunol 2001;101:249-63.
27. Momm F, Guttenberger R. Treatment of xerostomia following radiotherapy: does age matter?. Support Care Cancer 2002;10:505-8.
28. Leek H, Albertsson M. Pilocarpine treatment of xerostomia in head and neck patients. Micron 2002;33:153-5.
29. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall E, et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch Intern Med 2002;162:1293-300.
30. Schubert DS. The use of bethanechol chloride with phenothiazines: a case report. Am J Psychiatry 1979;136:110-1.
31. Wall GC, Magarity ML, Jundt JW. Pharmacotherapy of xerostomia in primary Sjögren's syndrome. Pharmacotherapy 2002;22:621-9.
32. Davies AN, Singer J. A comparison of artificial saliva and pilocarpine in radiation-induced xerostomia. J Laryngol Otol 1994;108:663-5.
33. Wynn RL, Meiller TF. Artificial saliva products and drugs to treat xerostomia. Gen Dent 2000;48:630-6.
34. Johansson G, Andersson G, Attstom R, Edwardsson S. Oral mucous membrane flora in patients using saliva substitutes. Gerodontology 2000;17:87-90.
35. Guijarro-Guijarro B, López-Sánchez AF, Hernández- Vallejo G. Tratamiento de la xetostomía. Una revisión. Medicina Oral 2001;6:7-18.
36. Tenuovo J. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety. Oral Dis 2002;8:23-9.